Sigilon Therapeutics recently announced a “strategic reprioritization,” as the company shifts focus to their non-hemophilia, investigational therapies, including those for MPS-1 and diabetes. This closely follows recent setbacks associated with…
For Immediate ReleaseMedia Contact:Ilana Ostriniostrin@hemophilia.org212-328-3769New York, NY -- The next generation of researchers are continuously inspiring and…
Results of a recently published study suggest that intense physical activities, particularly those that include a high collision-risk, can increase bleeding risk in individuals with severe or moderately severe hemophilia A. Investigators also found…
Val and I first got to know one another 30 years ago, when we were opposing one another in an election for president of the National Hemophilia Foundation (US). I was fighting for HIV/AIDS advocacy from within, from the Board, and Val was part of a…
FOR IMMEDIATE RELEASE
Media & Community Inquiries
Brett Spitale, VP of Advancement
Dec. 31, 2021 – New York, NY – NHF is deeply saddened to announce that former NHF CEO and community member, Val Bias, passed away suddenly…
WASHINGTON, D.C.— December 31, 2021 — In response to additional rulemaking for the Centers for Medicare & Medicaid Services’ (CMS) Notice of Benefit and Payment Parameters (NBPP) for 2023, the All Copays Count Coalition, which comprises more…
One patient changed Dr. Amy Dunn’s entire career the first-year of residency. It was then that Dr. Dunn diagnosed her first patient with hemophilia. She became “hooked” on hematology and “knew that it was the field for me.” Now the director of…
BioMarin recently shared a community update on their Hemophilia A Clinical Development Program for valoctocogene roxaparvovec, the company’s investigational gene therapy.
valoctocogene roxaparvovec is being investigated for safety and efficacy…
New Hemophilia Treatments: Implications for the Coagulation Laboratory
Speaker(s): Dr. Len Valentino
NHF's Wednesday Webinars are a free education series open to providers and…